From the 2010s onward, clinical translation accelerated with FDA-approved markers: BTA and NMP22 (bladder cancer) [824], and CA-125/HE4 (ROMA test for ovarian cancer) [377]. The gene discussed is MUC16; the disease is ovarian carcinoma.